- Home
- NKTX vs JHI Comparison
NKTX vs JHI Comparison
Compare NKTX & JHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NKTX
- JHI
- Stock Information
- Founded
- NKTX 2015
- JHI 1971
- Country
- NKTX United States
- JHI United States
- Employees
- NKTX N/A
- JHI N/A
- Industry
- NKTX Biotechnology: Pharmaceutical Preparations
- JHI Trusts Except Educational Religious and Charitable
- Sector
- NKTX Health Care
- JHI Finance
- Exchange
- NKTX Nasdaq
- JHI Nasdaq
- Market Cap
- NKTX 123.5M
- JHI 120.3M
- IPO Year
- NKTX 2020
- JHI N/A
- Fundamental
- Price
- NKTX $2.12
- JHI $14.00
- Analyst Decision
- NKTX Strong Buy
- JHI
- Analyst Count
- NKTX 6
- JHI 0
- Target Price
- NKTX $14.40
- JHI N/A
- AVG Volume (30 Days)
- NKTX 578.6K
- JHI 29.5K
- Earning Date
- NKTX 08-12-2025
- JHI 01-01-0001
- Dividend Yield
- NKTX N/A
- JHI 6.80%
- EPS Growth
- NKTX N/A
- JHI N/A
- EPS
- NKTX N/A
- JHI 1.05
- Revenue
- NKTX N/A
- JHI N/A
- Revenue This Year
- NKTX N/A
- JHI N/A
- Revenue Next Year
- NKTX N/A
- JHI N/A
- P/E Ratio
- NKTX N/A
- JHI $12.47
- Revenue Growth
- NKTX N/A
- JHI N/A
- 52 Week Low
- NKTX $1.31
- JHI $11.63
- 52 Week High
- NKTX $6.66
- JHI $13.40
- Technical
- Relative Strength Index (RSI)
- NKTX 57.92
- JHI 63.96
- Support Level
- NKTX $1.74
- JHI $13.86
- Resistance Level
- NKTX $2.32
- JHI $14.11
- Average True Range (ATR)
- NKTX 0.15
- JHI 0.07
- MACD
- NKTX 0.02
- JHI -0.00
- Stochastic Oscillator
- NKTX 62.96
- JHI 62.07
About NKTX Nkarta Inc.
Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.
About JHI John Hancock Investors Trust
John Hancock Investors Trust is a United States-based diversified, closed-end management investment company. It seeks to generate income for distribution to its shareholders. The secondary objective of the company is capital appreciation. The portfolio composition of the fund comprises corporate bonds, U.S. government agencies, preferred securities, asset-backed securities, common stocks, short-term investments, and others.